BackgroundE3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Interacts with SMAD1 and SMAD7 in order to trigger their ubiquitination and proteasome-dependent degradation. In addition, interaction with SMAD7 activates autocatalytic degradation, which is prevented by interaction with SCYE1. Forms a stable complex with the TGF-beta receptor-mediated phosphorylated SMAD2 and SMAD3. In this way, SMAD2 may recruit substrates, such as SNON, for ubiquitin-mediated degradation. Enhances the inhibitory activity of SMAD7 and reduces the transcriptional activity of SMAD2. Coexpression of SMURF2 with SMAD1 results in considerable decrease in steady-state level of SMAD1 protein and a smaller decrease of SMAD2 level.
DescriptionSMURF2 Polyclonal Antibody. Unconjugated. Raised in: Rabbit.
FormulationLiquid. 0.03% Proclin 300, 50% Glycerol, 0.01M PBS, PH 7.4.
SpecificityHuman
IsotypeIgG
Uniprot IDQ9HAU4
Purification>95%, Protein G purified
ImmunogenRecombinant Human E3 ubiquitin-protein ligase SMURF2 protein (1-748AA)
StorageShipped at 4°C. Upon delivery aliquot and store at -20°C (short-term) or -80°C (long-term). Avoid repeated freeze.
Alternative NamesE3 ubiquitin-protein ligase SMURF2 (EC:6.3.2.-), hSMURF2, SMURF2, SMAD ubiquitination regulatory factor 2, SMAD-specific E3 ubiquitin-protein ligase 2
ApplicationELISA, IHC; Recommended dilution: IHC:1:20-1:200